AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28505233 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone (DEX), ondansetron (OND), and droperidol (DRO) (Group B)
Number of subjects: 315
Study 28505233 — intervention group
Group type: COMPARATOR
Intervention: Combination of dexamethasone (DEX) and ondansetron (OND) (Group A)
Number of subjects: 315
Study 24903578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program
Number of subjects: 24
Study 24903578 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention program
Number of subjects: 24
Study 23972577 — intervention group
Group type: EXPERIMENTAL
Intervention: FD‐APAP 1000 mg
Number of subjects: 701
Study 23972577 — intervention group
Group type: EXPERIMENTAL
Intervention: FD‐APAP 500 mg
Number of subjects: 701
Study 23972577 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP 650 mg
Number of subjects: 701
Study 23972577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 22433304 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV 1.0 mg/d monotherapy
Number of subjects: 40
Study 22433304 — intervention group
Group type: COMPARATOR
Intervention: ETV + ADV 10 mg/d
Number of subjects: 40
Study 19454403 — intervention group
Group type: EXPERIMENTAL
Intervention: SGS (structured diabetes teaching and treatment programme)
Number of subjects: 155
Study 19454403 — intervention group
Group type: COMPARATOR
Intervention: Standard DTTP
Number of subjects: 155
Study 17014428 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus acidophilus LAVRI‐A1; Probiomics)
Number of subjects: 231
Study 17014428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin alone)
Number of subjects: 231
Study 12601511 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvicol( trademark ) implant
Number of subjects: 142
Study 10990104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (4 microg/kg per minute)
Number of subjects: 12
Study 10990104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8724378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic glucose solution (Group I)
Number of subjects: 21
Study 8724378 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and 20% long-chain triacylglycerides emulsion (Group II)
Number of subjects: 21
Study 8724378 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% emulsion of a mixture of medium-chain and long-chain triacylglycerides (Group III)
Number of subjects: 21
Study 1524959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 28
Study 1524959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3927062 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Ia - Glucose alone as energy source
Number of subjects: 61
Study 3927062 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Ib - Mixture of glucose and fructose
Number of subjects: 61
Study 3927062 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II - Specially formulated amino acid solution with glucose and fructose
Number of subjects: 61
Study 31792324 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic methods (microsatellite loci)
Number of subjects: 11
Study 31792324 — intervention group
Group type: EXPERIMENTAL
Intervention: Network analysis, causal modelling, multiple matrix regression with randomization
Number of subjects: 11
Study 29317275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose increases (2 maximum) in steps of 2.5 mg/kg based on clinical symptoms and biomarker analysis and/or serum infliximab concentrations (DIS1 group)
Number of subjects: 122
Study 29317275 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose increase from 5 to 10 mg/kg based on the same criteria (DIS2 group)
Number of subjects: 122
Study 29317275 — intervention group
Group type: COMPARATOR
Intervention: Dose increase to 10 mg/kg based on clinical symptoms alone (control group)
Number of subjects: 122
Study 28137501 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 1620
Study 28137501 — intervention group
Group type: COMPARATOR
Intervention: VI 25 μg
Number of subjects: 1620
Study 25511449 — intervention group
Group type: EXPERIMENTAL
Intervention: POLD technique (manual oscillatory therapy)
Number of subjects: 30
Study 25511449 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 30
Study 23443345 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal electrical stimulation with surface-EMG biofeedback (TVES + sEMG)
Number of subjects: 102
Study 21627406 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (30% protein, 40% carbohydrate, 30% lipid)
Number of subjects: 40
Study 21627406 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-protein diet (15% protein, 55% carbohydrate, 30% lipid)
Number of subjects: 40
Study 19141980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (rabeprazole, clarithromycin, and furazolidone)
Number of subjects: 307
Study 19141980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (ranitidine bismuth citrate, clarithromycin, and furazolidone)
Number of subjects: 307
Study 19141980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (rabeprazole, amoxicillin, and furazolidone)
Number of subjects: 307
Study 19141980 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (ranitidine bismuth citrate, amoxicillin, and furazolidone)
Number of subjects: 307
Study 16185755 — intervention group
Group type: EXPERIMENTAL
Intervention: MVAC (methotrexate 30 mg/m2 IV days 1, 15, and 22, vinblastine 3 mg/m2 IV days 2, 15, and 22, doxorubicin 30 mg/m2 IV day 2, cisplatin 70 mg/m2 day 2 of a 4-week cycle)
Number of subjects: 28
Study 16185755 — intervention group
Group type: COMPARATOR
Intervention: AC (doxorubicin 30 mg/m2 + cisplatin 70 mg/m2 IV q 4 weeks)
Number of subjects: 28
Study 12943180 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong (Shuxinpingxuegong)
Number of subjects: 58
Study 12943180 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 11215835 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 titration schedule (initial dosage 50 mg/d increased in 50 mg/d increments at weekly intervals)
Number of subjects: 188
Study 11215835 — intervention group
Group type: COMPARATOR
Intervention: 100/200 titration schedule (initial dosage 100 mg/d increased by 100-200 mg/d at weekly intervals)
Number of subjects: 188
Study 9034229 — intervention group
Group type: EXPERIMENTAL
Intervention: CaP/P tablet formulation
Number of subjects: 10
Study 9034229 — intervention group
Group type: EXPERIMENTAL
Intervention: CaP/GG tablet formulation
Number of subjects: 10
Study 8515293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan (2 g i.v. single dose)
Number of subjects: 561
Study 8515293 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin (2 g i.v. single dose)
Number of subjects: 561
Study 8515293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cefotetan and piperacillin
Number of subjects: 561
Study 3027841 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg daily for five days (women)
Number of subjects: 0
Study 3027841 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sexual partners of women)
Number of subjects: 0
Study 31044654 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy (AT)
Number of subjects: 62
Study 31044654 — intervention group
Group type: COMPARATOR
Intervention: Routine medical treatment (Control Group)
Number of subjects: 62
Study 29500079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intentional learning (explicit instructions)
Number of subjects: 48
Study 29500079 — intervention group
Group type: COMPARATOR
Intervention: Standard learning (no explicit instructions)
Number of subjects: 48
Study 25362247 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid injections combined with a single local injection of corticosteroid-lidocaine (Group 2)
Number of subjects: 70
Study 25362247 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular hyaluronic acid injections only (Group 1)
Number of subjects: 70
Study 24639149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (two doses of 510 mg 5 ± 3 days apart)
Number of subjects: 605
Study 24639149 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (five doses of 200 mg on five nonconsecutive days over 14 days)
Number of subjects: 605
Study 24639149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 605
Study 24639149 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose
Number of subjects: 605
Study 24639149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol and Iron sucrose
Number of subjects: 605
Study 23967637 — intervention group
Group type: EXPERIMENTAL
Intervention: Staging treatment group (acupuncture at tendon points, electric thermal needling, small needle-knife therapy, bleeding method, electric thermal therapy with thick silver needles)
Number of subjects: 180
Study 23967637 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) group (EA applied at Liangqiu (ST 34), Xuehai (SP 10), Yanglingquan (GB 34))
Number of subjects: 180
Study 21210610 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation experience
Number of subjects: 63
Study 21210610 — intervention group
Group type: COMPARATOR
Intervention: Traditional skills laboratory method
Number of subjects: 63
Study 21210610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 18005487 — intervention group
Group type: EXPERIMENTAL
Intervention: Food advertisements
Number of subjects: 59
Study 18005487 — intervention group
Group type: COMPARATOR
Intervention: Non-food adverts
Number of subjects: 59
Study 17236639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative spinal analgesia (IT group: bupivacaine or clonidine 300 microg)
Number of subjects: 0
Study 17236639 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative epidural analgesia (EPID group: bupivacaine, sufentanil, and clonidine 1 microg/kg)
Number of subjects: 0
Study 17236639 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia alone (GA group)
Number of subjects: 0
Study 12482554 — intervention group
Group type: COMPARATOR
Intervention: DHA (4 g/day)
Number of subjects: 59
Study 12482554 — intervention group
Group type: COMPARATOR
Intervention: EPA (4 g/day)
Number of subjects: 59
Study 12482554 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (olive oil)
Number of subjects: 59
Study 10839588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 138
Study 10839588 — intervention group
Group type: COMPARATOR
Intervention: Protease Inhibitor (PI)
Number of subjects: 138
Study 9316528 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 25 mg/day
Number of subjects: 116
Study 9316528 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day
Number of subjects: 116
Study 9316528 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg/day
Number of subjects: 116
Study 8403674 — intervention group
Group type: EXPERIMENTAL
Intervention: Local antibiotics (Septopal) alone
Number of subjects: 0
Study 8403674 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotics or combined treatment
Number of subjects: 0
Study 8403674 — intervention group
Group type: COMPARATOR
Intervention: Parenteral antibiotics
Number of subjects: 0
Study 2883060 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms SMS 201-995 twice daily
Number of subjects: 9
Study 2883060 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms SMS 201-995
Number of subjects: 9
Study 2883060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31584341 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of distal radial fractures
Number of subjects: 0
Study 30384149 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain evaluative threat condition
Number of subjects: 0
Study 30384149 — intervention group
Group type: COMPARATOR
Intervention: Negative evaluative threat condition
Number of subjects: 0
Study 27287207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment (n = 179)
Number of subjects: 361
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (Arm A; n = 7)
Number of subjects: 23
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (Arm B; n = 6)
Number of subjects: 23
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (Arm C; n = 5)
Number of subjects: 23
Study 24974131 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa-2b plus ribavirin (Arm D; n = 5)
Number of subjects: 23
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SVR in female patients receiving OHA
Number of subjects: 23
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SVR in male patients
Number of subjects: 23
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Per protocol analysis for Acarbose (Arm A)
Number of subjects: 23
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Per protocol analysis for Metformin (Arm B)
Number of subjects: 23
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Per protocol analysis for Pioglitazone (Arm C)
Number of subjects: 23
Study 24974131 — intervention group
Group type: COMPARATOR
Intervention: Per protocol analysis for Peginterferon alfa-2b plus ribavirin (Arm D)
Number of subjects: 23
Study 24974131 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients receiving OHA
Number of subjects: 23
Study 23323329 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipin
Number of subjects: 0
Study 23323329 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 0
Study 23323329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidol
Number of subjects: 0
Study 23323329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20549525 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy treatment for postpartum depression
Number of subjects: 176
Study 20549525 — intervention group
Group type: COMPARATOR
Intervention: Never depressed postpartum women
Number of subjects: 176
Study 18514501 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA supplementation for 15 weeks
Number of subjects: 129
Study 18514501 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 weeks
Number of subjects: 129
Study 18514501 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA+MVM for 15 weeks (after initial 15 weeks)
Number of subjects: 129
Study 18514501 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional micronutrient supplementation
Number of subjects: 129
Study 20590369 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic wave therapy (AWT) using extracorporeal pulse activation technology (EPAT)
Number of subjects: 25
Study 20590369 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated legs)
Number of subjects: 25
Study 16324360 — intervention group
Group type: EXPERIMENTAL
Intervention: UTI 5000 U/kg given one hour after injury, 3 times/day
Number of subjects: 52
Study 16324360 — intervention group
Group type: EXPERIMENTAL
Intervention: UTI 400,000 U IV drop bid for 7 days
Number of subjects: 52
Study 16324360 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment with fluid resuscitation and wound management, normal saline IV drop bid for 7 days
Number of subjects: 52
Study 12193353 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming at 52 degrees C
Number of subjects: 140
Study 12193353 — intervention group
Group type: COMPARATOR
Intervention: Passive insulation (heater not activated)
Number of subjects: 140
Study 12193353 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming
Number of subjects: 140
Study 12193353 — intervention group
Group type: COMPARATOR
Intervention: Passive insulation
Number of subjects: 140
Study 9502350 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (A)
Number of subjects: 20
Study 9502350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 20
Study 9502350 — intervention group
Group type: COMPARATOR
Intervention: First cycle ergometer test (F)
Number of subjects: 20
Study 8018759 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition (PPN)
Number of subjects: 84
Study 8018759 — intervention group
Group type: COMPARATOR
Intervention: Conventional serum therapy
Number of subjects: 84
Study 2692645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and postoperative radiotherapy
Number of subjects: 500
Study 2692645 — intervention group
Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 500
Study 4920816 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 11739866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diacylglycerol (DG) oil (target dose 10 g/d) for 12 weeks
Number of subjects: 16
Study 11739866 — intervention group
Group type: COMPARATOR
Intervention: Ordinary TG cooking oil (control group)
Number of subjects: 16
Study 30561577 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual azithromycin distributions
Number of subjects: 0
Study 30561577 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30097357 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0
Study 30097357 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemoradiotherapy
Number of subjects: 0
Study 30097357 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival adjusted for quality of life
Number of subjects: 0
Study 26248651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Coping Online (CCO)
Number of subjects: 60
Study 26248651 — intervention group
Group type: COMPARATOR
Intervention: Web-based attention control
Number of subjects: 60
Study 25277215 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic cholecystectomy
Number of subjects: 0
Study 25277215 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 0
Study 22364141 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) 400/100 mg BID + raltegravir (RAL) 400 mg BID
Number of subjects: 60
Study 22364141 — intervention group
Group type: COMPARATOR
Intervention: sHAART
Number of subjects: 60
Study 22364141 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) + raltegravir (RAL)
Number of subjects: 60
Study 20163864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost gel suspension applied to the base of the eyelashes every evening for 6 weeks
Number of subjects: 19
Study 20163864 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline gel suspension) applied to the base of the eyelashes every evening for 6 weeks
Number of subjects: 19
Study 20163864 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bimatoprost and placebo)
Number of subjects: 19
Study 18069761 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine trypsinogen-2 dipstick test (UTDT)
Number of subjects: 92
Study 18069761 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-pancreatic causes)
Number of subjects: 92
Study 16006724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2 mg/day
Number of subjects: 40
Study 16006724 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg/day
Number of subjects: 40
Study 12422138 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 108
Study 10359733 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (GP IIb/IIIa inhibitor)
Number of subjects: 100
Study 10359733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 10359733 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide or Placebo
Number of subjects: 100
Study 7576753 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy with radiation
Number of subjects: 0
Study 7576753 — intervention group
Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 0
Study 7576753 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated patients
Number of subjects: 0
Study 7576753 — intervention group
Group type: EXPERIMENTAL
Intervention: NSABP-B06 trial
Number of subjects: 0
Study 7576753 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I good prognosis patients
Number of subjects: 0
Study 7576753 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I poor prognosis patients
Number of subjects: 0
Study 1835293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with smoking cessation and placebo inhaler
Number of subjects: 5887
Study 1835293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention with smoking cessation and ipratropium bromide
Number of subjects: 5887
Study 1835293 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5887
Study 6269234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 50
Study 6269234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 6269234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (follow-up after initial treatment)
Number of subjects: 50
Study 6269234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (follow-up after initial treatment)
Number of subjects: 50
Study 31839104 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin preoperative neoadjuvant chemotherapy (Group A)
Number of subjects: 82
Study 31839104 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment after preoperative examination (Group B)
Number of subjects: 82
Study 28711708 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe and simvastatin combination
Number of subjects: 20
Study 28711708 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 26239086 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant von Willebrand factor (rVWF)
Number of subjects: 22
Study 24307269 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurexal (test product)
Number of subjects: 23
Study 24307269 — intervention group
Group type: COMPARATOR
Intervention: Lyrica (reference product)
Number of subjects: 23
Study 22447014 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination pill (losartan 50mg/hydrochlorothiazide 12.5mg)
Number of subjects: 207